Array Biopharma (ARRY) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.30 -3.23%
EPS Growth %: -70.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: -70.0%
Financial Fact:
License and milestone revenue: 1.66M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $44.52 million versus the consensus estimate of $30.99 million.
COLUMBUS / BRAF-mutant melanoma New Drug Application (NDA) expected to file in June or July
NEMO / NRAS-mutant melanoma target action date under the Prescription Drug User Fee Act (PDUFA) on June 30, 2017
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Knowles (KN) Tops Q3 EPS by 2c; offers guidance
- Marten Transport (MRTN) Misses Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, FDA, GuidanceRelated Entities
Earnings, PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
